The Medical Letter on Drugs and Therapeutics
Two New Amphetamines for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Two new extended-release amphetamine products have been approved by the FDA for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old: Adzenys XR-ODT (Neos Therapeutics), an orally distintegrating tablet, and Dyanavel XR (Tris Pharma), an oral suspension.

AMPHETAMINES FOR ADHD — Amphetamines generally have been as effective as methylphenidate in decreasing overactivity, impulsivity, and inattention in children with ADHD. Some children who have not responded to methylphenidate may respond to an amphetamine, and vice versa. Racemic amphetamine sulfate, mixed amphetamine salts, dextroamphetamine, and lisdexamfetamine dimesylate, an oral prodrug of dextroamphetamine, vary in duration of action, but appear to be similar in efficacy.1,2 All stimulants used for treatment of ADHD are classified as Schedule II ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Amphetamines for ADHD
Article code: 1497c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian